Therapeutic Candidates

Broad SIGMACEPTOR Discovery Platform Targeting Significant Unmet Medical Needs

 
 
 
 
 

Our SIGMACEPTOR Discovery Platform consists of differentiated clinical-stage CNS assets targeting significant and growing markets. Anavex Life Sciences has patent protection to 2030-2039. World-wide rights for all listed product candidates.